lactucin: structure in first source
lactucin : An azulenofuran that is 3-methylidene-3,3a,4,5,9a,9b-hexahydroazuleno[4,5-b]furan-2,7-dione carrying additional hydroxy, methyl and hydroxymethyl substituents at positions 4, 6 and 9 respectively (the 3aR,4S,9aS,9bR-diastereomer). Found in chicory.
ID Source | ID |
---|---|
PubMed CID | 442266 |
CHEBI ID | 6358 |
SCHEMBL ID | 14215975 |
MeSH ID | M0506217 |
Synonym |
---|
C09489 |
1891-29-8 |
lactucin |
vjqaflazrvkakm-vzliptousa- |
inchi=1/c15h16o5/c1-6-3-9(17)12-7(2)15(19)20-14(12)13-8(5-16)4-10(18)11(6)13/h4,9,12-14,16-17h,2-3,5h2,1h3/t9-,12+,13-,14-/m0/s1 |
(3ar,4s,9as,9br)-4-hydroxy-9-(hydroxymethyl)-6-methyl-3-methylidene-4,5,9a,9b-tetrahydro-3ah-azuleno[4,5-b]furan-2,7-dione |
AC1L9CIQ , |
r6e2918904 , |
unii-r6e2918904 |
azuleno(4,5-b)furan-2,7-dione, 3,3a,4,5,9a,9b-hexahydro-4-hydroxy-9-(hydroxymethyl)-6-methyl-3-methylene-, (3ar-(3aalpha,4beta,9aalpha,9bbeta))- |
lactucine |
(3ar,4s,9as,9br)-3,3a,4,5,9a,9b-hexahydro-4-hydroxy-9-(hydroxymethyl)-6-methyl-3-methyleneazuleno(4,5-b)furan-2,7-dione |
lactucin [mi] |
SCHEMBL14215975 |
CHEBI:6358 |
(3ar,4s,9as,9br)-4-hydroxy-9-(hydroxymethyl)-6-methyl-3-methylidene-3,3a,4,5,9a,9b-hexahydroazuleno[4,5-b]furan-2,7-dione |
(3ar,4s,9as,9br)-4-hydroxy-9-(hydroxymethyl)-6-methyl-3-methylene-4,5,9a,9b-tetrahydro-3ah-azuleno[4,5-b]furan-2,7-dione |
DTXSID70894751 |
(3ar,4s,9as,9br)-4-hydroxy-9-(hydroxymethyl)-6-methyl-3-methylene-3,3a,4,5-tetrahydroazuleno[4,5-b]furan-2,7(9ah,9bh)-dione |
HY-N9438 |
CS-0169537 |
AKOS040763768 |
FS-7317 |
Excerpt | Reference | Relevance |
---|---|---|
"Lactucin-treated cells fail to undergo mitotic clonal expansion (MCE)." | ( A Potential Nutraceutical Candidate Lactucin Inhibits Adipogenesis through Downregulation of JAK2/STAT3 Signaling Pathway-Mediated Mitotic Clonal Expansion. Cai, GH; Chen, Y; Chu, XY; Liu, H; Liu, M; Lu, JF; Shi, XC; Wang, X; Wang, YL; Wu, JW; Xia, B; Xie, BC; Yang, SZ; Zhang, CC; Zhang, DY; Zhang, RX; Zhu, MQ, 2020) | 1.55 |
Role | Description |
---|---|
antimalarial | A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. |
sedative | A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
sesquiterpene lactone | Any member of a diverse class of complex, multicyclic phytochemicals showing a variety of skeleton arrangements and bioactivities, and having in common a sesquiterpenoid structure including a lactone ring. |
azulenofuran | |
cyclic terpene ketone | An alicyclic ketone in which the carbocyclic ring structure forms part of a terpene skeleton. |
enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (10.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 3 (30.00) | 24.3611 |
2020's | 5 (50.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (44.94) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |